SkinBioTherapeutics (SBTX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

8.00p
   
  • Change Today:
      0.25p
  • 52 Week High: 26.10
  • 52 Week Low: 5.20
  • Currency: UK Pounds
  • Shares Issued: 259.04m
  • Volume: 2,901,537
  • Market Cap: £20.72m
  • Beta: 0.39

SBTX Overview

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CSO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

1 Day Chart (27-02-2026)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -24.2% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 4.5 n/a
Pr/Book 2.2  
Latest F'cast
Revenue 283.7% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

SBTX Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-21 n/a (1.50) (0.01)p n/a n/a n/a n/a 0.0%
30-Jun-22 0.07 (2.99) (1.78)p n/a n/a n/a n/a 0.0%
30-Jun-23 0.13 (3.01) (1.72)p n/a n/a n/a n/a 0.0%
30-Jun-24 1.21 (2.95) (1.54)p n/a n/a n/a n/a 0.0%
30-Jun-25 4.64 (0.72) (0.31)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

SBTX Company Announcements

Independent Investigation Appointment 20-Feb-2026 07:00 RNS
Update on Board Investigation 16-Feb-2026 07:00 RNS
Resignation of CEO 13-Feb-2026 07:00 RNS

SBTX ShareCast News

Skinbiotherapeutics brings in new audit chair, l... 20-Feb-2026 ShareCast
SkinBioTherapeutics dives on warning of major FY... 16-Feb-2026 ShareCast
SkinBioTherapeutics CEO resigns 13-Feb-2026 ShareCast

SBTX Top Newspaper Links

SkinBioTherapeutics dives after sudden exit of c... 18-Feb-2026 Times

Latest SBTX Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

SBTX Market Data

Currency UK Pounds
Share Price 8.00p
Change Today 0.25p
% Change 3.23 %
52 Week High 26.10
52 Week Low 5.20
Volume 2,901,537
Shares Issued 259.04m
Market Cap £20.72m
Beta 0.39

SBTX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
71.12% below the market average71.12% below the market average71.12% below the market average71.12% below the market average71.12% below the market average
75.61% below the sector average75.61% below the sector average75.61% below the sector average75.61% below the sector average75.61% below the sector average
Price Trend
36.07% below the market average36.07% below the market average36.07% below the market average36.07% below the market average36.07% below the market average
9.09% below the sector average9.09% below the sector average9.09% below the sector average9.09% below the sector average9.09% below the sector average
Income Not Available
Growth
49.92% above the market average49.92% above the market average49.92% above the market average49.92% above the market average49.92% above the market average
72.41% above the sector average72.41% above the sector average72.41% above the sector average72.41% above the sector average72.41% above the sector average

SBTX Dividends

No dividends found

Trades for 27-Feb-2026

Time Volume / Share Price
16:35 18,500 @ 8.00p
16:35 1,500 @ 8.00p
16:35 17,000 @ 8.00p
16:23 1,176 @ 8.50p
16:23 200 @ 8.50p

SBTX Key Personnel

CEO Stuart Ashman
CFO Emily Bertram

Top of Page